The complement system is an innate immune response that leads to increased inflammation. The drug pegcetacoplan—a complement inhibitor—was approved for medical use in the United States in 2021 to ...

Please provide your email address to receive an email when new articles are posted on . Hospitalizations with vs. without pathway use were shorter and cost less. Significantly more ...

Pathway will retain its brand and operate independently as Clearlake’s investment solutions business Pathway’s leadership team will remain intact The company was founded in 1991 Clearlake Capital ...

SAN FRANCISCO -- The investigational complement-targeting agent claseprubart was safe and led to significant improvements in generalized myasthenia gravis (MG), the phase II MaGic trial showed. The ...

Forbes contributors publish independent expert analyses and insights. Victor Dey is an analyst and writer covering AI and emerging tech. Pathway claims to have uncovered the mathematical blueprint of ...

Positive results from Phase 2 MaGic trial including additional analyses, and new preclinical data highlighting potential benefits of upstream inhibition, to be presented for claseprubart in ...

The objective of this study was to evaluate the methodology to establish the hemolytic activity of alternative complement pathway as an indicator of the innate immunity in Brazilian fish pacu ...

Creative Commons (CC): This is a Creative Commons license. Attribution (BY): Credit must be given to the creator. The interactions of nanoparticles (NPs) with macrophages after intravenous injection ...

Health tech company Doximity bought Pathway Medical to bulk up its healthcare artificial intelligence capabilities as it looks to offer more free AI tools to doctors. The transaction closed July 29 ...

ARO-C3 treatment led to deep and sustained reductions in alternative pathway complement activity and proteinuria. ARO-C3, an investigational RNA interference-based therapy targeting hepatic expression ...